TRIAMCINOLONE ACETONIDE FDA MedWatch Direct Reports Summary

These tables and charts are created from 622 voluntary U.S. reports for TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE ACETONIDE) reported by individuals to the FDA via the MedWatch Reporting System from 2004 through April 28, 2026.

For a summary of adverse events including mandatory reports submitted by pharmaceutical companies (all countries and all reporter types) to the FAERS database, View FDA FAERS TRIAMCINOLONE ACETONIDE Report.

Top Adverse Effects Associated with TRIAMCINOLONE ACETONIDE (from U.S. FDA Medwatch Reports)

	Side Effect	# of FDA Reports
1	RASH	53
2	ITCHING	47
3	DRUG INEFFECTIVE	36
4	SKIN REDNESS	34
5	PAIN	34
6	SKIN PEELING	32
7	NAUSEA	29
8	DIZZINESS	24
9	HEADACHE	24
10	INSOMNIA	24
11	DEATH	21
12	DIARRHEA	21
13	SHORTNESS OF BREATH	20
14	STEROID WITHDRAWAL SYNDROME	18
15	CONDITION AGGRAVATED	17
16	ECZEMA	17
17	FATIGUE	17
18	HIVES	17
19	FEELING ABNORMAL	16
20	THERAPY INTERRUPTED	16
21	LACK OF STRENGTH AND ENERGY (ASTHENIA)	15
22	HYPERSENSITIVITY	15
23	PRODUCT PACKAGING CONFUSION	15
24	PAIN IN EXTREMITY	14
25	VOMITING	14

Search all MedWatch Reports by Keyword:

TRIAMCINOLONE ACETONIDE Total Medwatch Safety Reports by Patient Sex

Male	Female	Unknown	Total
210	367	45	622

Medwatch Reporter Type	Count
Consumer	261
Physician	42
Pharmacist	97
Other Health Professional	116

Top Indications

Product used for unknown indication
Psoriasis
Intervertebral disc protrusion
JOINT PAIN
Multiple sclerosis

Type of Outcome Reported
Serious: 413
Not Serious: 209
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Suspected Role
Primary Suspect: 622
Concomitant Drugs: 482
Note: A single MedWatch report can list more than one drug. This summary includes TRIAMCINOLONE ACETONIDE identified as the suspect drug or as a concomitantly taken drug.

FDA Safety-Related Labeling Changes

KENALOG-10 (TRIAMCINOLONE ACETONIDE) Rx Drug:
FDA Safety-related Labeling Changes

Risk of infection with various pathogens, including viral, bacterial, fungal, protozoan, or helminthic (parasitic)

KENALOG-40 (TRIAMCINOLONE ACETONIDE) Rx Drug:
FDA Safety-related Labeling Changes

ZILRETTA (TRIAMCINOLONE ACETONIDE) Rx Drug:
FDA Safety-related Labeling Changes

Have experience (good or bad) with ZILRETTA? Rate ZILRETTA at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

NOTES

This report, created by AskaPatient.com, is derived from U.S. drug-related adverse event cases that were reported directly to the FDA using the voluntary MedWatch online or paper reporting system. MedWatch is the voluntary FDA system for consumers, physicians, and others to directly report adverse reactions. The Medwatch initiative was launched in 1993 as a voluntary reporting program for consumers, physicians and other healthcare practitioners.

After processing the received forms, the FDA adds the MedWatch reports to the FDA Adverse Events Reporting System(or FAERS database.) Click here for the complete FAERS report summary, which includes mandatory reports submitted by pharmaceutical companies (worldwide) combined with the MedWatch reports. MedWatch Reports only represent about 5% of the FAERS database. For more, read "Does the FDA's Rapidly Growing Database of Adverse Events Improve Drug Safety?"

The data in this report was obtained from Open FDA. Data was last updated to include reports through January 27, 2026. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event.

Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on Open FDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions about this report.